The transactions highlighted below are representative of Greenhill engagements. In addition, the Firm has completed many engagements that were not publicly-disclosed.
Recent Transactions
Sort By
Faster S.p.A.
Advised Capvis, one of the leading buyout firms in Switzerland, on the acquisition of Faster S.p.A., one of the top 2 global manufacturers of quick-release hydraulic couplings
MannKind Corporation
Advised MannKind, a biopharmaceutical company focused on the development of therapeutic products for patients with diabetes, on a collaboration with Sanofi, comprising licensing, supply and loan facility agreements with respect to licensing the Company’s lead product AFREZZA. MannKind will receive up to $925 million in upfront and milestone payments plus 35% of future profits.
Siemens Health Services
Advised Cerner Corporation, a leader in healthcare information services, on the acquisition of the assets of Siemens Aktiengesellschaft’s healthcare information technology business unit, Siemens Health Services, for $1.3 billion in cash.
TUI Travel Plc
Advised TUI AG on the merger with TUI Travel Plc creating the world’s number one integrated leisure tourism business (+Transaction value represents enterprise value of combined entity)
Flint Group
Advised Flint Group, a portfolio company of CVC Capital Partners and a global leader in the manufacturing of printing inks and consumables on its sale to a consortium consisting of Goldman Sachs Merchant Banking and the private equity arm of Koch Industries
Forest Laboratories Inc.
Advised Actavis plc, a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products on its acquisition of Forest Laboratories Inc.
Warner Chilcott, plc
Advised Actavis, Inc., a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, branded and biosimilar products on its acquisition of Warner Chilcott plc
Mediclinic International Limited
Advised Mediclinic International, South Africa’s second largest and Switzerland’s largest provider of private hospital services, on the restructuring of its entire balance sheet, including $2.2 billion debt refinancing in Switzerland and a $0.6 billion rights issue in South Africa
Minority stake in Stadler Rail
Advised Capvis, one of the leading buyout firms in Switzerland and one of the main mid-market private equity firms in German-speaking Europe, on the staged exit from of its 20% minority stake in Stadler Rail, by selling to Peter Spuhler, CEO and majority shareholder in Stadler Rail
Solar PV power plant in Italy
Advised Antin Infrastructure Partners on the acquisition of a c.20MW solar PV power plant in Italy
Citigroup (selected private equity assets)
Advised AXA Private Equity, a leading European diversified private equity firm, on its acquisition of a $1.7 billion portfolio of limited partnership interests in private equity buyout funds and a portfolio of direct stakes in companies from Citigroup
Alcon, Inc.
Advised the Independent Director Committee of Alcon, Inc., an ophthalmic pharmaceutical company, on the sale of Alcon’s outstanding publicly held interest to Novartis AG, a global pharmaceutical company
Enzon Pharmaceuticals, Inc.
Advised Enzon Pharmaceuticals, Inc., a biopharmaceutical company on the sale of its specialty pharmaceutical business to Sigma-Tau, an Italian pharmaceutical company
Genentech, Inc.
Advised Roche Holding Ltd., a world-leading provider of healthcare pharmaceuticals and diagnostics, on its acquisition of the outstanding publicly held interest in Genentech, Inc., a leading biotechnology company
Ventana Medical Systems, Inc.
Advised Roche Holding Ltd., a world-leading provider of healthcare pharmaceuticals and diagnostics, on its acquisition of Ventana Medical Systems, Inc., a US based provider of histopathology diagnostic equipment
Schering AG
Advised Bayer on its public offer for Schering, an international pharmaceuticals group based in Berlin, Germany
Drakkar Holdings SA (Adisseo Group)
Advised CVC Capital Partners on the divestiture of Adisseo via the sale of Drakkar Holdings SA to China National BlueStar, a subsidiary of state-owned diversified chemicals company China National Chemical Corporation. Adisseo is a leading player in the animal nutrition market
Minit Group
(wholly owned by UBS Capital)
Advised UBS Capital on its sale of the Minit Group, the world's largest shoe repair and key cutting services chain, to CVC Capital Partners
Pages
- « first
- ‹ previous
- 1
- 2
- 3